EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access · CC BY 4.0

Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial

Håvard Midgard iD, Kristian Braathen Malme, Charlotte Meinich Pihl, Riikka Mari Berg-Pedersen, Lars Tanum, Ingvild Klundby, Anne Haug, Ida Tveter, Ronny Bjørnestad, Inge Christoffer Olsen, Ane-Kristine Finbråten, Olav Dalgard

Clinical Infectious Diseases · 20.03.2024 · 78 (3) · 582-590

DOI: 10.1093/cid/ciad711 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 22.11.2023. Verfasst von Håvard Midgard und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Drug Users, Hepatitis C, Hepatitis C, Chronic, Substance Abuse, Intravenous. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Southern and Eastern Norway Regional Health Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to evaluate the efficacy of opportunistic treatment of hepatitis C virus (HCV) infection among hospitalized people who inject drugs (PWID).

Methods

We performed a pragmatic, stepped wedge cluster randomized trial recruiting HCV RNA positive individuals admitted for inpatient care in departments of internal medicine, addiction medicine, and psychiatry at three hospitals in Oslo, Norway. Seven departments were sequentially randomized to change from control conditions (standard of care referral to outpatient care) to intervention conditions (immediate treatment initiation). The primary outcome was treatment completion, defined as dispensing the final package of the prescribed treatment within six months after enrolment.

Results

A total of 200 HCV RNA positive individuals were enrolled between 1 October 2019 and 31 December 2021 (mean age 47.4 years, 72.5% male, 60.5% injected past 3 months, 20.4% cirrhosis). Treatment completion was accomplished by 67 of 98 (68.4% [95% confidence interval {CI}: 58.2–77.4]) during intervention conditions and by 36 of 102 (35.3% [95% CI: 26.1–45.4]) during control conditions (risk difference 33.1% [95% CI: 20.0–46.2]; risk ratio 1.9 [95% CI: 1.4–2.6]). The intervention was superior in terms of treatment completion (adjusted odds ratio [aOR] 4.8 [95% CI: 1.8–12.8]; P = .002) and time to treatment initiation (adjusted hazard ratio [aHR] 4.0 [95% CI: 2.5–6.3]; P < .001). Sustained virologic response was documented in 60 of 98 (61.2% [95% CI: 50.8–70.9]) during intervention and in 66 of 102 (64.7% [95% CI: 54.6–73.9]) during control conditions.

Conclusions

An opportunistic test-and-treat approach to HCV infection was superior to standard of care among hospitalized PWID. The model of care should be considered for broader implementation. Clinical Trials Registration. NCT04220645

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug UsersHepatitis CHepatitis C, ChronicSubstance Abuse, IntravenousFemaleHumansMaleMiddle AgedAntiviral AgentsHepacivirusRNA

Stichwörter der Autor:innen

hepatitis C virusmodel of carepeople who inject drugspragmatic clinical trialstepped wedge cluster randomized trial

Substanzen

Antiviral AgentsRNA

Autor:innen und Institutionen

  • Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.
  • Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.
  • Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.
  • Department of Addiction Medicine, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Håvard Midgard

Förderung

  • Southern and Eastern Norway Regional Health Authority

Zitieren

APA

Midgard, H., Malme, K. B., Pihl, C. M., Berg-Pedersen, R. M., Tanum, L., Klundby, I., Haug, A., Tveter, I., Bjørnestad, R., Olsen, I. C., Finbråten, A. K., & Dalgard, O. (2024). Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial. Clinical Infectious Diseases, 78(3), 582-590. https://doi.org/10.1093/cid/ciad711

Vancouver

Midgard H, Malme KB, Pihl CM, Berg-Pedersen RM, Tanum L, Klundby I, et al. Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial. Clinical Infectious Diseases. 2024;78(3):582-590. doi:10.1093/cid/ciad711

BibTeX
@article{Midgard2024,
  author = {Midgard, Håvard and Malme, Kristian Braathen and Pihl, Charlotte Meinich and Berg-Pedersen, Riikka Mari and Tanum, Lars and Klundby, Ingvild and Haug, Anne and Tveter, Ida and Bjørnestad, Ronny and Olsen, Inge Christoffer and Finbråten, Ane-Kristine and Dalgard, Olav},
  title = {Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {3},
  pages = {582--590},
  doi = {10.1093/cid/ciad711}
}
Kostenlos starten →